Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
Halozyme sues Merck over subcutaneous Keytruda
Halozyme alleges in a lawsuit that a subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.
Angus Liu
Apr 24, 2025 2:41pm
Merck CEO talks strategy amid tariff, policy uncertainty
Apr 24, 2025 11:27am
Akeso's fast-rising ivonescimab scores 3rd lung cancer trial win
Apr 23, 2025 11:30am
Gilead's Trodelvy-Keytruda proposal hits goal in first-line TNBC
Apr 21, 2025 11:29am
Merck CEO Rob Davis' 2024 pay climbed 13% to $23.2M
Apr 10, 2025 11:50am
Merck lays out subcutaneous Keytruda data amid patent brawl
Mar 27, 2025 11:00am
